The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.
 
Kazuhiro Tanaka
Honoraria - Eisai; Novartis; Taiho Pharmaceutical
 
Ryunosuke Machida
No Relationships to Disclose
 
Akira Kawai
Honoraria - Daiichi Sankyo; Eisai; Lilly; Novartis; Otsuka; Taiho Pharmaceutical; Takara Bio
 
Robert Nakayama
No Relationships to Disclose
 
Satoshi Tsukushi
No Relationships to Disclose
 
Kunihiro Asanuma
No Relationships to Disclose
 
Yoshihiro Matsumoto
Honoraria - Eisai
 
Hiroaki Hiraga
Honoraria - Eisai; Hisamitsu Pharmaceutical; Kaken Pharmaceutical; Novartis; Taiho Pharmaceutical
Research Funding - Lilly Japan (Inst)
 
Koji Hiraoka
No Relationships to Disclose
 
Munenori Watanuki
Travel, Accommodations, Expenses - Eisai
 
Tsukasa Yonemoto
No Relationships to Disclose
 
Satoshi Abe
No Relationships to Disclose
 
Hirohisa Katagiri
Honoraria - Daiichi Sankyo
 
Yoshihiro Nishida
Honoraria - Astellas Pharma; Chugai Pharma; Daiichi Sankyo
Consulting or Advisory Role - Seikagaku
Research Funding - Novartis
 
Akihito Nagano
No Relationships to Disclose
 
Yoshiyuki Suehara
Research Funding - Loxo
 
Tomoko Kataoka
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Toshifumi Ozaki
No Relationships to Disclose
 
Yukihide Iwamoto
No Relationships to Disclose